Clinical studies assessing the use of colchicine in patients with chronic coronary syndromes
| Study, * | Study design | Colchicine dose and duration | Clinical setting | Patient number | Main results |
| Kajikawa et al 37 | Randomised trial | Colchicine 0.5 mg daily for 7 days | Stable CAD | 28 | Colchicine improved FMD only in the subgroup of patients with higher leucocyte count >7500/mm3 |
| Nidorf et al (LoDoCo trial)41 | Randomised trial | Colchicine 0.5 mg daily for a median of 36 months plus statins and standard secondary prevention drugs | Stable CAD | 532 | Colchicine reduced cardiovascular events (ACS, out-of-hospital cardiac arrest, non-cardioembolic ischaemic stroke): 5.3% vs 16% (HR 0.33, 95% CI 0.18 to 0.59) |
| Deftereos et al 47 | Randomised trial | Colchicine 0.5 mg twice daily for 6 months | Diabetic, stable CAD patients undergoing PCI with a bare-metal stent | 196 | Colchicine reduced in-stent restenosis rate (16% vs 33%, p=0.007) |
| Nidorf and Thompson36 | Prospective study | Colchicine 0.5 mg twice daily for 1 month plus aspirin and high-dose atorvastatin | Stable CAD patients with elevated hs-CRP | 64 | Reduction of hs-CRP (from 4.58±2.05 mg/L to 1.78±1.38 mg/L, p<0.001) |
*From most recent studies.
ACS, acute coronary syndrome; CAD, coronary artery disease; CRP, C reactive protein; FMD, flow-mediated vasodilation; hs-CRP, high-sensitivity C reactive protien; LoDoCo, Low-Dose Colchicine; PCI, percutaneous coronary intervention.